期刊
PHARMACEUTICS
卷 13, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13101690
关键词
levetiracetam; augmented renal clearance; intensive care; critically ill patients; population pharmacokinetic; modelling; Monte Carlo simulations; seizure
资金
- Department of Education of the Basque Government [PIBA 2019-57]
- University of the Basque Country UPV/EHU [GIU20/048, PIFG19/23]
This study evaluated the dosing of Levetiracetam in ICU patients with normal or augmented renal clearance (ARC), finding that CrCl influenced the drug clearance rate, with normal renal function patients requiring 500mg/8h or 1000mg/12h, and ARC patients needing higher doses.
Levetiracetam is a broad-spectrum antiepileptic drug commonly used in intensive care units (ICUs). The objective of this study is to evaluate the adequacy of levetiracetam dosing in patients with normal or augmented renal clearance (ARC) admitted to the ICU by population modelling and simulation. A multicentre prospective study including twenty-seven critically ill patients with urinary creatinine clearance (CrCl) > 50 mL/min and treated with levetiracetam was developed. Levetiracetam plasma concentrations were best described by a two-compartment model. The parameter estimates and relative standard errors (%) were clearance (CL) 3.5 L/h (9%), central volume of distribution (V1) 20.7 L (18%), intercompartmental clearance 31.9 L/h (22%), and peripheral volume of distribution 33.5 L (13%). Interindividual variability estimates were, for the CL, 32.7% (21%) and, for V1, 56.1% (29%). The CrCl showed significant influence over CL. Simulations showed that the administration of at least 500 mg every 8 h or 1000 mg every 12 h are needed in patients with normal renal function. Higher doses (1500 or 2000 mg, every 8 h) are needed in patients with ARC. Critically ill patients with normal or ARC treated with levetiracetam could be at high risk of being underdosed.yy
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据